Product Description: LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research[1].
Applications: COVID-19-immunoregulation
Formula: C20H24N6O3
References: [1]Kostich W, et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358(3):371-86./[2]Mushtaq, et al. Role Of Endocytic Machinery Regulators in EGFR Traffic and Viral Entry (2021). Theses & Dissertations. 532.
CAS Number: 1454555-29-3
Molecular Weight: 396.44
Compound Purity: 99.74
Research Area: Infection; Inflammation/Immunology; Neurological Disease
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: AAK1;Cyclin G-associated Kinase (GAK);SARS-CoV
Deutsch
English
